[WT1 peptide-based immunotherapy].
The Wilms' tumor gene WT1 is overexpressed in leukemia and various types of solid cancers and its product is a tumor rejection antigen. A phase I clinical trials of WT1 peptide-based cancer immunotherapy were performed with good clinical response but with only skin reaction at the injection sites of WT1 vaccine. Thus, WT1-targeting immunotherapy should be promissing.
Sugiyama
Haruo
H
Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine.
D000230:Adenocarcinoma / Q000628:therapy; D000328:Adult; D000368:Aged; D000754:Anemia, Refractory, with Excess of Blasts / Q000628:therapy; D000818:Animals; D001943:Breast Neoplasms / Q000628:therapy; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D025721:WT1 Proteins / Q000009:adverse effects / Q000627:therapeutic use*
D019496:Cancer Vaccines; D025721:WT1 Proteins